重度子痫前期采用硝苯地平缓释片联合拉贝洛尔方案的疗效分析

Efficacy of nifedipine sustained release tablets combined with labetalol hydrochloride in the treatment of severe preeclampsia

目的 探讨重度子痫前期采用硝苯地平缓释片联合盐酸拉贝洛尔方案的疗效.方法 选取忻州市人民医院2015年1月至2018年1月收治的重度子痫前期患者100例,按照随机数字表法分为对照组和观察组,每组50例,对照组实施硝苯地平缓释片治疗,观察组实施硝苯地平缓释片联合盐酸拉贝洛尔辅助治疗,比较两组疗效、病情控制时间、住院时间;观察治疗前后患者舒张压、动脉压、24 h尿蛋白定量变化;观察产后出血、胎儿窘迫、胎盘早剥、新生儿窒息等母婴并发症发生率;观察产妇心悸、血压下降等不良反应发生率.结果 观察组总有效率[100.00% (50/50)]高于对照组[80.00% (40/50)],差异有统计学意义(x2=8.145,P<0.05);观察组治疗后的舒张压[(80.56±1.21) mmHg]、动脉压[(114.19±12.50) mmHg]、24 h尿蛋白定量[(1.01±0.21)g]低于对照组[(85.46±1.56) mmHg、(131.21±12.51) mmHg、(2.21±0.32)g](t=7.935、16.355、4.823,均P<0.05);观察组病情控制时间[(3.46±0.45)d]、住院时间[(19.34±2.24)d]均短于对照组[(5.46±1.21)d和(10.23±1.41)d],差异均有统计学意义(t=6.268、6.145,均P<0.05);观察组产后出血、胎儿窘迫、胎盘早剥、新生儿窒息等母婴并发症发生率[10.00%(5/50)]低于对照组[24.00%(12/50)],差异有统计学意义(x2 =6.924,P<0.05);观察组产妇心悸、血压下降等不良反应发生率[4.00%(2/50)]低于对照组[16.00% (8/50)],差异有统计学意义(x2=6.644,P<0.05).结论 硝苯地平缓释片联合盐酸拉贝洛尔辅助治疗重度子痫前期可获得较好预后,可有效减少母婴不良结局的发生,有效改善产妇的生命体征和减少蛋白尿,加速疾病控制,缩短住院的时间.

Objective To investigate the fficacy of nifedipine sustained-release tablets combined with labetalol hydrochloride regimen in the treatment of severe preec lampsia.Methods From January 2015 to January 2018,100 patients with severe preeclampsia admitted to the Peoples Hospital of Xinzhou were selected.According to the random number table method,they were divided into control group and observation group,with 50 cases in each group.The control group was treated with nifedipine sustained-release tablets,while the observation group was treated with nifedipine sustained-release tablets combined with labetalol hydrochloride as adjuvant therapy.The curative effects;the time of disease control,the average lengh of hospital stay;the average diastolie blood pressure,average arterial pressure,24-hour urinary protein quantification of patients before and after treatment;the incidences of maternal and infant complications such as postpartum hemorrhage,fetal distress.placental premature beats,neonatal asphyxia;the incidence of adverse reactions such as palpitation and hypotension in parturients of the two groups were compared.Results The total ffctive rate of the observation group was 100.00%(50/50),which was higher than that of the control group[80.00%(40/50)],the diference was satistically signifcant(χ2=8.145,P<0.05).After treatment,the mean diastolice blood pressure[(80.56±1.21)mmHg],mean arterial pressure[(114.19±12.50)mmHg],24-hour urinary protein quantification[(1.01±0.21)g]in the observation group were lower than those in the control group[(85.46±1.56)mmHg,(131.21±12.51)mmHg,(2.21±0.32)g)](1=7.935,16.355.4.823,all P<0.05).The time of disease control[(3.46±0.45)d]and the average hospitalization time[(19.34±2.24)d]in the observation group were shorter than those in the control group(5.46±1.21)d and(10.23±1.41)d,the differences were statistically significant(1=6.268,6.145,all P<0.05).The incidence of complications such as postpartum hemorrhage,fetal distress,placental premature beats and neonatal asphyxia in the observation group was 10.00%(5/50),which was lower than that in the control group 24.00%(12/50),the difference was statistically significant(χ2=6.924,P<0.05).The ineidence of adverse reactions such as palpitation and blood pressure drop in the observation group was 4.00%(2/50),which was lower than that in the control group[16.00%(8/50)],the difference was statistically significant(χ2=6.644,P<0.05).Conclusion Nifedipine sustained-release tablets combined with labetalol hydrochloride adjuvant therapy for severe preclampsia can obtain better prognosis,ffectively reduce the occurrence of adverse outcomes of mothers and infants,efctively improve maternal vital signs and reduce proteinuria,accelerate disease control,shorten hospitalization time.